| P2093 | author name string | Bodrey Ro | |
| | Christine Nelson | |
| | Elizabeth Stillman | |
| | Jennifer C Woo | |
| | Mia MacPhail | |
| | Roderick S Tang | |
| | Rosemary Sweetwood | |
| | Shahin Aslam | |
| | Stacie L Lambert | |
| | Yuk Man Lei | |
| P2860 | cites work | Respiratory syncytial virus vaccine development | Q56893551 |
| | The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo | Q79485051 |
| | Toll-like receptors: linking innate and adaptive immunity | Q81808287 |
| | Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant | Q21091066 |
| | Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers | Q27667876 |
| | Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes | Q27668015 |
| | A synthetic adjuvant to enhance and expand immune responses to influenza vaccines | Q28748680 |
| | T-cell quality in memory and protection: implications for vaccine design | Q30014840 |
| | Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection | Q30442832 |
| | Respiratory syncytial virus nephropathy in rats | Q33268031 |
| | Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection | Q33781375 |
| | Modulation of adaptive immunity with Toll-like receptors | Q34016666 |
| | Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A | Q34532064 |
| | Palivizumab in the prevention of respiratory syncytial virus disease | Q34974757 |
| | Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells | Q34977848 |
| | IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. | Q35069985 |
| | GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults | Q35669044 |
| | Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention | Q35778982 |
| | An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice | Q36500189 |
| | Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review | Q36593301 |
| | Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein | Q36606731 |
| | Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells | Q36797478 |
| | Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein | Q36838539 |
| | Fc-receptors as regulators of immunity. | Q36991445 |
| | Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. | Q37071608 |
| | Age-related decline in immunity: implications for vaccine responsiveness | Q37150322 |
| | Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer | Q37287399 |
| | IL-17A inhibits airway reactivity induced by respiratory syncytial virus infection during allergic airway inflammation | Q37562241 |
| | Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys | Q37568127 |
| | Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice | Q37587807 |
| | Particulate vaccines: on the quest for optimal delivery and immune response. | Q37875382 |
| | Respiratory syncytial virus infection in adult populations | Q37984109 |
| | Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion | Q38284074 |
| | Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology | Q38958797 |
| | Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. | Q39328333 |
| | Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing | Q39746492 |
| | Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations | Q39800494 |
| | Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion | Q39812986 |
| | Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity | Q40513366 |
| | Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. | Q42235080 |
| | Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects. | Q42357177 |
| | Duration of antiviral immunity after smallpox vaccination | Q43485360 |
| | Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults | Q43979004 |
| | IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses | Q44918119 |
| | Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children | Q45363218 |
| | A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. | Q45382330 |
| | Experimental infection of humans with A2 respiratory syncytial virus | Q45571445 |
| | Risk factors for severe respiratory syncytial virus infection in elderly persons | Q45699277 |
| | CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). | Q45735797 |
| | CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection | Q45757956 |
| | Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine | Q45762897 |
| | Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment | Q45763190 |
| | Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. | Q45765792 |
| | Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. | Q45767285 |
| | Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum | Q45777706 |
| | Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. | Q45828600 |
| | Immunity to and frequency of reinfection with respiratory syncytial virus | Q45853042 |
| | Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles | Q48004357 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| P304 | page(s) | e0119509 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models | |
| P478 | volume | 10 | |